Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma. - Urman A; Ding Y; Durham J; Wang H; Qi H; Narang A; Burkhart R; He J; Le D; Laheru D; Thompson E; Jaffee E; et al. (Frontiers in immunology, 2026)